2022
Oncologic outcomes of neoadjuvant chemotherapy in patients with micropapillary variant urothelial carcinoma of the bladder
Rahman S, Lokeshwar S, Syed J, Javier-Desloges J, Press B, Choksi A, Rajwa P, Pradere B, Ploussard G, Kim J, Monaghan T, Renzulli J, Shariat S, Leapman M. Oncologic outcomes of neoadjuvant chemotherapy in patients with micropapillary variant urothelial carcinoma of the bladder. Urologic Oncology Seminars And Original Investigations 2022, 41: 107.e1-107.e8. PMID: 36481253, DOI: 10.1016/j.urolonc.2022.09.008.Peer-Reviewed Original ResearchConceptsVariant urothelial carcinomaNeoadjuvant chemotherapySubset of patientsUrothelial carcinomaOverall survivalPathologic responseRadical cystectomyNAC useClinical stage II diseaseHospital-based registry studyNeoadjuvant platinum-based chemotherapyPathologic lymph node positivityCox proportional hazards modelNational Cancer DatabaseStage II diseaseLymph node positivityPathologic complete responsePlatinum-based chemotherapyKaplan-Meier analysisMultivariable logistic regressionAnalysis of patientsBladder urothelial carcinomaProportional hazards modelCT2 diseasePathologic upstaging
2020
PT414 Similar survival outcomes among chemoradiation and neoadjuvant chemotherapy with radical cystectomy for small cell bladder cancer
Abello A, Renzulli J, Park H, Leapman M, Kenney P. PT414 Similar survival outcomes among chemoradiation and neoadjuvant chemotherapy with radical cystectomy for small cell bladder cancer. European Urology Open Science 2020, 19: e2283. DOI: 10.1016/s2666-1683(20)34148-3.Peer-Reviewed Original ResearchPD55-02 SIMILAR SURVIVAL OUTCOMES AMONG CHEMORADIATION AND NEOADJUVANT CHEMOTHERAPY WITH RADICAL CYSTECTOMY FOR SMALL CELL BLADDER CANCER
Abello* A, Nawaf C, Renzulli J, Park H, Leapman M, Kenney P. PD55-02 SIMILAR SURVIVAL OUTCOMES AMONG CHEMORADIATION AND NEOADJUVANT CHEMOTHERAPY WITH RADICAL CYSTECTOMY FOR SMALL CELL BLADDER CANCER. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000965.02.Peer-Reviewed Original ResearchSmall cell bladder cancerSimilar survival outcomesNeoadjuvant chemotherapySurvival outcomesBladder cancer
2019
PD66-04 NATIONAL TRENDS AND PATHOLOGIC OUTCOMES OF NEOADJUVANT CHEMOTHERAPY AMONG PATIENTS WITH MICROPAPILLARY VARIANT UROTHELIAL CARCINOMA OF THE BLADDER
Javier-DesLoges* J, Abello A, Syed J, Sprenkle P, Hurwitz M, Kenney P, Leapman M. PD66-04 NATIONAL TRENDS AND PATHOLOGIC OUTCOMES OF NEOADJUVANT CHEMOTHERAPY AMONG PATIENTS WITH MICROPAPILLARY VARIANT UROTHELIAL CARCINOMA OF THE BLADDER. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000557466.16539.88.Peer-Reviewed Original ResearchNational trends and pathologic outcomes of neoadjuvant chemotherapy among patients with micropapillary variant urothelial carcinoma of the bladder.
Javier-Desloges J, Abello A, Syed J, Leapman M. National trends and pathologic outcomes of neoadjuvant chemotherapy among patients with micropapillary variant urothelial carcinoma of the bladder. Journal Of Clinical Oncology 2019, 37: 477-477. DOI: 10.1200/jco.2019.37.7_suppl.477.Peer-Reviewed Original ResearchUse of NACUrothelial cell carcinomaReceipt of NACNeoadjuvant chemotherapyMicropapillary variantPathologic responseEntire cohortCell carcinomaClinical stage II diseasePropensity scoreVariant urothelial carcinomaNational Cancer DatabaseStage II diseaseComplete pathologic responsePathologic complete responseAggressive clinical behaviorLogistic regression modelsCT2 diseasePT0 rateComplete responsePathologic characteristicsRadical cystectomyDistant metastasisHistological diagnosisNAC use